News

Compared to other forms of CBT, pharmacotherapy, and no treatment, digital CBT offered a more than $640 net positive benefit in 94.7% of Markov model simulations.

The chief scientific officer of the Parkinson’s Foundation discussed what has previously been observed in genetic Parkinson disease and what gaps the PD GENEration initiative may fill.

COVID-19 positive patients with Guillain-Barre syndrome were predominately of demyelinating subtype and appeared more severe than non-COVID-19 patients with Guillain-Barré syndrome.

The findings of a prospective, multicenter study support the results of previous single center studies.

A net benefit was observed for all functional outcomes across the entire range of the modified Rankin Scale despite an increased risk of symptomatic intracranial hemorrhage.

The executive VP and chief research officer of MDA spoke about how the new visualization reporting platform will also allow for easy recruitment of data to be used in future clinical trials and research studies.

Only small, nonsignificant improvements were observed in Unified Parkinson’s Disease Rating Scale motor scores, though the investigators did not report disease worsening with early treatment.

The professor of neurology at the NYU Langone Grossman School of Medicine outlined the confusion on whether deaths are related to COVID-19, a symptom associated, or previously unidentified underlying condition.

Researchers developed the biomarker in hopes of simplifying the recent MRPI 2.0 measurement for use in clinical practice.

The professor of clinical neurology at University of Miami and MT2020+ chair discussed the initiative’s effort to improve the global accessibility of mechanical thrombectomy.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD GENEration initiative tackles 1 of the greatest unmet needs for patients with Parkinson disease.

Leigh Charvet, PhD, discusses the adoption and potential of validated digital and tele-based approaches for the treatment of multiple sclerosis.

The EXTEND and EPITHET trials selected patients by perfusion mismatch rather than the less sensitive noncontrast computed tomography, the findings providing reassurance of consistency for thrombolysis-induced reperfusion.

The vascular neurologist at Memorial Hermann Medical Group discusses how stroke care has been affected throughout the COVID-19 pandemic.

Veronica Hood, PhD, of the Dravet Syndrome Foundation, details the recently accepted ICD-10 codes for Dravet syndrome and what benefit they bring to patients.